Drug Profile
Celecoxib/lisinopril - Adhera Therapeutics
Alternative Names: IT 102Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator IthenaPharma
- Developer Adhera Therapeutics
- Class Analgesics; Antihypertensives; Antineoplastics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules
- Mechanism of Action ACE inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hypertension
- Discontinued Arthritis; Cancer; Inflammation; Pain
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Hypertension in USA
- 02 May 2019 Discontinued - Clinical-Phase-Unknown for Inflammation in USA (Adhera Therapeutics pipeline, May 2019)
- 02 May 2019 Discontinued - Preclinical for Arthritis in USA (Adhera Therapeutics pipeline, May 2019)